Patents by Inventor Rachel Prorok

Rachel Prorok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROGRANULIN VARIANTS
    Publication number: 20230265137
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 24, 2023
    Publication date: August 24, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • Progranulin variants
    Patent number: 11643446
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: May 9, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L. Y. Low, Rachel Prorok, Ankita Srivastava
  • PROGRANULIN VARIANTS
    Publication number: 20220220172
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 14, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava
  • PROGRANULIN VARIANTS
    Publication number: 20220213155
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 7, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220177576
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 9, 2022
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis Kariolis, Cathal Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220119522
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: April 21, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220073609
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: August 16, 2021
    Publication date: March 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Sherie Duncan, Kathleen Lisaingo, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Ju Shi, Ankita Srivastava, Bettina Van Lengerich, Riley Walsh
  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 11124567
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: September 21, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210214438
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • PROGRANULIN VARIANTS
    Publication number: 20210188925
    Abstract: Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.
    Type: Application
    Filed: January 26, 2021
    Publication date: June 24, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Gerald Maxwell Cherf, Gunasekaran Kannan, Katrina W. Lexa, Ray L.Y. Low, Rachel Prorok, Ankita Srivastava